Skip to main content
. 2021 Jul 1;76:105656. doi: 10.1016/j.ultsonch.2021.105656

Fig. 19.

Fig. 19

(a) TMP of the MBR for a given permeate flux as a function of time with and without O3/US pre-treatment prior to MBR and (b) The removal of pharmaceutical compounds (DCF, CBZ and SMX) after different treatments: O3/US treatment, MBR process and O3/US followed by MBR in series [209].